We’re committed to developing potentially transformational medicines to address the needs of patients with hematologic malignancies. With more than 90 abstracts, we’re sharing the latest data from our industry-leading portfolio at #ASH24: t.co/ErhqNhYpJY #JNJOncology t.co/mjL5cJ9up7